A U.S. District judge says the most efficient justice would come from linking the cases in a class action.
A union pension fund is suing Pfizer (NYSE: PFE) and its board, alleging that directors ignored signs that the drugmaker was playing fast and loose with off-label marketing. The fund blames the
Pfizer's lawyers have been busy lately. Deal-making, due diligence, whistleblower lawsuits, off-label marketing settlements--you name it. Here's a roundup of recent news courtesy of the company's
The ex-Pfizer sales manager sentenced for off-label promotion of the Bextra painkiller told Massachusetts officials that the company not only knew about her off-label activities, but encouraged them.
We thought yesterday was all Wy-Pfi, all the time, but today's news line-up may even beat that. As the initial surprise wore off and folks started digging, a host of new angles emerged on the big
News of the Pfizer-Wyeth merger this morning drowned out some not so good news for the company. Just after announcing its $68 billion buyout of Wyeth, Pfizer published its 2008 fourth quarter
Pfizer can now say "done deal" on most of the lawsuits over its painkillers Celebrex and Bextra. The cost? $894 million. As of today, the drugmaker has reached agreements in principle to settle with
Pfizer is starting to settle the thousands of lawsuits over painkillers Celebrex and Bextra, the Wall Street Journal reports. Three groups of plaintiffs who allege that the meds caused heart attacks